Hill-Rom (NYSE: HRC) demoted by Stifel Nicolaus

Hill-Rom (NYSE: HRC) was downgraded by Stifel Nicolaus from a “buy” rating to a “conservation” rating in a report released Friday, The Fly reports.

Several other equity research analysts have also recently published reports on the HRC. Bank of America downgraded Hill-Rom’s stock from a “buy” rating to a “neutral” rating and set a target price of $ 130.00 for the stock. in a report on Tuesday August 10. Morgan Stanley downgraded Hill-Rom’s stock rating from “overweight” to “on par” and raised its price target for the company from $ 148.00 to $ 156.00 in a report research on Sunday, September 19. Robert W. Baird downgraded Hill-Rom shares from “outperforming” to “neutral” and raised their price target for the company from $ 150.00 to $ 156.00 in a report research on Friday, September 3. Finally, KeyCorp downgraded Hill-Rom shares from an “overweight” rating to an “industry-weighted” rating in a Wednesday, September 8 research note. Five research analysts rated the stock with a conservation rating and one gave the stock a buy rating. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $ 141.80.

NYSE: HRC shares traded down $ 0.02 at noon on Friday, reaching $ 155.07. 10,474 shares of the stock traded for an average volume of 664,223. The stock has a market cap of $ 10.21 billion, a PE ratio of 43.70 and a beta of 0.54. The company’s 50-day moving average is $ 151.06 and its two-hundred-day moving average is $ 129.53. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt ratio of 0.81. Hill-Rom has a one-year low of $ 88.11 and a one-year high of $ 155.34.

(A d)

To wake up. Get some coffee. Turn on your computer… In 13 minutes… you could be 98% richer… Go play golf… or tennis… or whatever you want.

It’s easy… if you follow a few simple instructions.

Hill-Rom (NYSE: HRC) last reported its quarterly results on Friday, November 5. The medical technology company reported earnings per share of $ 1.67 for the quarter, beating the Zacks consensus estimate of $ 1.47 by $ 0.20. The company posted revenue of $ 797.90 million for the quarter, compared to analysts’ expectations of $ 752.97 million. Hill-Rom had a net margin of 8.12% and a return on equity of 21.74%. The company’s turnover is up 13.1% compared to the same quarter last year. In the same quarter of the previous year, the company achieved earnings per share of $ 1.17. As a group, sell-side analysts predict Hill-Rom will post 6.11 earnings per share for the current year.

Several institutional investors and hedge funds have recently bought and sold HRC shares. Bedel Financial Consulting Inc. increased its position in Hill-Rom by 43.0% in the second quarter. Bedel Financial Consulting Inc. now owns 502 shares of the medical technology company valued at $ 57,000 after acquiring 151 additional shares during the period. The Lombard Odier SCmA Company acquired a new position in Hill-Rom during the second quarter valued at approximately $ 62,000. Northwestern Mutual Wealth Management Co. increased its stake in Hill-Rom by 150.5% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 704 shares of the medical technology company valued at $ 80,000 after purchasing an additional 423 shares during the period. Carroll Financial Associates Inc. increased its stake in Hill-Rom shares by 21.9% in the third quarter. Carroll Financial Associates Inc. now owns 563 shares of the medical technology company valued at $ 84,000 after purchasing 101 additional shares during the period. Finally, Key Financial Inc bought a new position in Hill-Rom shares in the second quarter valued at approximately $ 87,000. Hedge funds and other institutional investors hold 76.45% of the company’s shares.

Hill-Rom Company Profile

Hill-Rom Holdings, Inc. operates as a medical technology company. The company is focused on patient care solutions that improve clinical and economic outcomes. It operates through the following segments: patient support system, primary care and surgical solutions. The Patient Support Systems segment provides bed frames and surfaces, mobility solutions and clinical workflow.

Featured article: Technical indicators – What is a golden cross?

The fly logo

Analyst Recommendations for Hill-Rom (NYSE: HRC)

This instant news alert was powered by narrative science technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in Hill-Rom now?

Before you consider Hill-Rom, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts quietly whisper to their clients to buy now before the larger market takes hold of… and Hill-Rom was not on the list.

While Hill-Rom currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here

Source link

About Palmer Mohler

Check Also

Anaplan (NYSE: PLAN) Receives New Price Target of $ 101.00 at Monness Crespi & Hardt

Anaplan (NYSE: PLAN) saw its target price lifted by research analysts at Monness Crespi & …